Next Article in Journal
Communication between B-Cells and Microbiota for the Maintenance of Intestinal Homeostasis
Next Article in Special Issue
Human Cytolytic Fusion Proteins: Modified Versions of Human Granzyme B and Angiogenin Have the Potential to Replace Bacterial Toxins in Targeted Therapies against CD64+ Diseases
Previous Article in Journal
Development of an Antibody for Detection of Rhamnolipids Characterized as a Major Bacterial Virulence Factor
Previous Article in Special Issue
Ricin and Ricin-Containing Immunotoxins: Insights into Intracellular Transport and Mechanism of action in Vitro
Antibodies 2013, 2(3), 517-534; doi:10.3390/antib2030517
Review

T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications

 and *
Faculty of Biology, Technion-Israel Institute of Technology, Haifa 32000, Israel
* Author to whom correspondence should be addressed.
Received: 15 August 2013 / Revised: 22 August 2013 / Accepted: 22 August 2013 / Published: 17 September 2013
(This article belongs to the Special Issue Recombinant Immunotoxins)
View Full-Text   |   Download PDF [215 KB, uploaded 17 September 2013]

Abstract

Major histocompatibility complex (MHC) class I molecules are key in the immune response against malignant cells by shaping the T-cell repertoire and presenting peptides from endogenous antigens to CD8+ cytotoxic T cells. Because of their unique specificity, MHC-peptide complexes are a desirable target for novel immunotherapeutic approaches. These complexes can be targeted by recombinant T-cell receptors (TCRs). However, most TCRs produced thus far have affinities which are too low for target detection under normal assay conditions, and limited stability (due to their generation in a single-chain version). Developing high-affinity soluble antibody molecules endowed with a TCR-like specificity toward tumor epitopes, termed TCR-like antibodies, addresses the low affinity of TCRs. These TCR-like antibodies are being developed as a new immunotherapeutic class for targeting tumor cells and mediating their specific killing. In addition, these antibodies are valuable research reagents enabling the study of human class I peptide-MHC ligand-presentation and TCR–peptide–MHC interactions.
Keywords: antibodies; antibody engineering; immunotoxins; MHC-peptide complex; phage display; recombinant antibodies; T-cell receptor; cancer immunotherapy antibodies; antibody engineering; immunotoxins; MHC-peptide complex; phage display; recombinant antibodies; T-cell receptor; cancer immunotherapy
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).
SciFeed

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
RIS
MDPI and ACS Style

Cohen, M.; Reiter, Y. T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications. Antibodies 2013, 2, 517-534.

View more citation formats

Related Articles

Article Metrics

Comments

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert